fda compounding glp-1 warning letters september 2025 Sends to More Than 50 Compounders and Manufacturers Congress Introduces SAFE Drugs Act

The broader benefits beyond glucose control are increasingly recognised in clinical decision-making, though prescribing decisions should be individualised based on patient characteristics, comorbidities, and treatment goals

Tendon & Ligament Research Researchers commonly use BPC-157 in models involving tendons, ligaments, and connective tissues

In December 2025, the Food and Drug Administration (FDA) approved an oral pill form of Wegovy for weight loss, and in April 2026 approved the once-daily oral GLP-1 drug Foundayo (orforglipron) also for weight loss

Our team is available to answer product and order-related questions